Cathepsin D in ovarian cancer:: prognostic value and correlation with p53 expression and microvessel density

被引:55
作者
Lösch, A
Schindl, M
Kohlberger, P
Lahodny, J
Breitenecker, G
Horvat, R
Birner, P
机构
[1] Univ Vienna, Clin Inst Pathol, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Gynecol & Obstet, A-1090 Vienna, Austria
[3] Hosp St Polten, Dept Gynecol & Obstet, A-3100 St Polten, Austria
关键词
cathepsin D; ovarian cancer; prognosis; p53; angiogenesis;
D O I
10.1016/j.ygyno.2003.11.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objective. Overexpression of ubiquitous lysosomal aspartyl protease cathepsin D (CD) is involved in the progression of cancer. This study investigates the prognostic value and the association of cathepsin D expression with clinicopathological parameters, p53 expression, and angiogenesis in ovarian cancer. Methods. Cathepsin D was determined immunohistochemically in 43 ovarian tumors of low malignant potential (LMP) and 80 invasive tumors FIGO stage I-IV. Results were correlated with clinicopathological characteristics, p53, and microvessel density (MVD). Survival analysis of cathepsin D expression and MVD was performed in invasive tumors. Results. Epithelial tumor cathepsin D expression was more common in LMP tumors (65.1%) compared to invasive tumors (43.7%; P = 0.02). In LMP tumors, stromal cathepsin D was associated with mucinous tumors (P = 0.01), whereas in invasive tumors, epithetial cathepsin D expression was associated with clear cell tumors (P = 0.003). Invasive tumor cathepsin D had a negative relation to p53 expression. In LMP tumors, stromal cathepsin D correlated with microvessel density (P = 0.03). Stromal cathepsin D expression was an independent prognostic factor for disease-free survival (DFS) in patients with invasive cancer (P = 0.03, Cox regression), while cathepsin D expression missed to be of prognostic value for overall survival (OS) in invasive ovarian cancer. MVD had no influence on survival in invasive ovarian cancer (P > 0.05). Conclusion. Our study demonstrates a prognostic value of cathepsin D expression in invasive ovarian cancer, while cathepsin D expression in LMP rumors seems to be linked to angiogenesis. The relation among cathepsin D, p53 expression, and angiogenesis demonstrates biological differences between invasive ovarian cancer and LMP tumors. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:545 / 552
页数:8
相关论文
共 36 条
[1]
Athanassiadou P, 1998, Pathol Oncol Res, V4, P103
[2]
The significance of metastasis-related factors cathepsin-D and nm23 in advanced ovarian cancer [J].
Baekelandt, M ;
Holm, R ;
Tropé, CG ;
Nesland, JM ;
Kristensen, GB .
ANNALS OF ONCOLOGY, 1999, 10 (11) :1335-1341
[3]
Modulation of proliferation and chemosensitivity by procathepsin D and its peptides in ovarian cancer [J].
Bazzett, LB ;
Watkins, CS ;
Gercel-Taylor, C ;
Taylor, DD .
GYNECOLOGIC ONCOLOGY, 1999, 74 (02) :181-187
[4]
Cathepsin-D affects multiple tumor progression steps in vivo:: proliferation, angiogenesis and apoptosis [J].
Berchem, G ;
Glondu, M ;
Gleizes, M ;
Brouillet, JP ;
Vignon, F ;
Garcia, M ;
Liaudet-Coopman, E .
ONCOGENE, 2002, 21 (38) :5951-5955
[5]
Birner P, 2001, CLIN CANCER RES, V7, P1661
[6]
COX DR, 1972, J R STAT SOC B, V34, P187
[7]
Cathepsin D and prognosis in breast cancer: One piece of a larger puzzle? [J].
EmmertBuck, MR .
HUMAN PATHOLOGY, 1996, 27 (09) :869-871
[8]
Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer [J].
Falcón, O ;
Chirino, R ;
León, L ;
López-Bonilla, A ;
Torres, S ;
Fernández, L ;
Garcia-Hernández, JA ;
Valerón, PF ;
Díaz-Chico, JC .
BRITISH JOURNAL OF CANCER, 1999, 79 (3-4) :570-576
[9]
Immunoradiometric and immunohistochemical analysis of cathepsin D in ovarian cancer: lack of association with clinical outcome [J].
Ferrandina, G ;
Scambia, G ;
Fagotti, A ;
D'Agostino, G ;
Panici, PB ;
Carbone, A ;
Mancuso, S .
BRITISH JOURNAL OF CANCER, 1998, 78 (12) :1645-1652
[10]
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients [J].
Foekens, JA ;
Look, MP ;
Bolt-de Vries, J ;
Meijer-van Gelder, ME ;
van Putten, WLJ ;
Klijn, JGM .
BRITISH JOURNAL OF CANCER, 1999, 79 (02) :300-307